PMID- 28490885
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 10
DP  - 2017
TI  - Treatment-related severe and fatal adverse events with molecular targeted agents 
      in the treatment of advanced gastric cancer: a meta-analysis.
PG  - 2281-2287
LID - 10.2147/OTT.S110431 [doi]
AB  - AIM: To perform a systematic review and meta-analysis of Phase III randomized 
      controlled trials (RCTs) to determine the incidence and risk of severe adverse 
      events (AEs) with molecular targeted agents (MTAs) in advanced/metastatic gastric 
      cancer (GC) patients. METHODS: A comprehensive literature search for related 
      trials published up to December 2015 was performed. Eligible studies were Phase 
      III RCTs of advanced/metastatic GC patients assigned to MTAs or control group. 
      Data were extracted by two authors for severe and fatal AEs (FAEs). RESULTS: A 
      total of nine Phase III RCTs involved 4,934 GC patients were ultimately 
      identified. The pooled results demonstrated that the addition of TAs to therapies 
      in advanced GC significantly increased the risk of developing severe AEs 
      (relative risk: 1.12, 95% confidence interval: 1.02-1.24, P=0.02), but not for 
      FAEs (relative risk: 0.97, 95% confidence interval: 0.65-1.45, P=0.88). 
      Additionally, the most common causes of FAEs with MTAs were infections (16.3%), 
      gastrointestinal hemorrhage (8.2%), and arterial thromboembolic events (8.2%), 
      respectively. CONCLUSION: With available evidence, the use of TAs in GC patients 
      was associated with an increased risk of severe AEs, but not for FAE. Clinicians 
      should be aware of the risk of severe AEs with the administration of these drugs 
      in these patients.
FAU - Wang, Liang
AU  - Wang L
AD  - Department of General Surgery, The Central Cangzhou Hospital, Cangzhou, Hebei 
      Province, People's Republic of China.
FAU - Liu, Yagang
AU  - Liu Y
AD  - Department of General Surgery, The Central Cangzhou Hospital, Cangzhou, Hebei 
      Province, People's Republic of China.
FAU - Zhou, Wenyong
AU  - Zhou W
AD  - Department of General Surgery, The Central Cangzhou Hospital, Cangzhou, Hebei 
      Province, People's Republic of China.
FAU - Li, Wei
AU  - Li W
AD  - Department of General Surgery, The Central Cangzhou Hospital, Cangzhou, Hebei 
      Province, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170426
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5414625
OTO - NOTNLM
OT  - advanced gastric cancer
OT  - meta-analysis
OT  - molecular targeted agents
OT  - randomized
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/05/12 06:00
MHDA- 2017/05/12 06:01
PMCR- 2017/04/26
CRDT- 2017/05/12 06:00
PHST- 2017/05/12 06:00 [entrez]
PHST- 2017/05/12 06:00 [pubmed]
PHST- 2017/05/12 06:01 [medline]
PHST- 2017/04/26 00:00 [pmc-release]
AID - ott-10-2281 [pii]
AID - 10.2147/OTT.S110431 [doi]
PST - epublish
SO  - Onco Targets Ther. 2017 Apr 26;10:2281-2287. doi: 10.2147/OTT.S110431. 
      eCollection 2017.